Omeros (OMER) Expected to Announce Quarterly Earnings on Monday

Omeros (NASDAQ:OMER) is anticipated to release its earnings data after the market closes on Monday, March 24th. Analysts expect Omeros to post earnings of ($0.69) per share for the quarter.

Omeros Stock Performance

OMER stock opened at $9.10 on Friday. The company has a fifty day moving average price of $8.70 and a 200-day moving average price of $7.32. The company has a market capitalization of $527.35 million, a P/E ratio of -3.94 and a beta of 2.03. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60.

Analyst Ratings Changes

Several research firms have recently issued reports on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, January 17th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Friday. Finally, StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.